IGF2BP1 targets ETV6/RUNX1, and the stability of its transcript mediates leukemogenesis in t(12; 21)(p13; q22)-positive ALL (Stoskus et al. 2016b). The gene discussed is IGF2BP1; the disease is acute lymphoblastic leukemia.